K2M reported its 2017 preliminary fourth-quarter and full-year results.
Here are the company's fourth quarter results:
1. K2M will likely see revenue between $67.3 million and $67.9 million, reflecting a 9 percent to 10 percent year-over-year increase.
2. Domestically, the revenue will land somewhere between $51.7 million and $52 million, a 9 percent year-over-year boost.
3. Specifically, the company's U.S. complex spine line grew 8 percent year-over-year and the minimally invasive surgery line grew 15 percent year-over year. The U.S. degenerative segment saw an 8 percent boost year-over-year.
4. K2M's international revenue hit between $15.6 million and $15.9 million, an 11 percent to 13 percent increase year-over-year.
Here are K2M's FY 2017 results:
5. The company reported revenue between $257.5 million $258.1 million, a 9 percent year-over-year increase.
6. K2M anticipates its full-year 2017 net loss and adjusted EBITDA to reflect its reported guidance.